DPYD Testing: Time to Put Patient Safety First
- PMID: 36821823
- PMCID: PMC10414691
- DOI: 10.1200/JCO.22.02364
DPYD Testing: Time to Put Patient Safety First
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
No other potential conflicts of interest were reported.
Comment in
-
Consent in Pharmacogenetic Testing.J Clin Oncol. 2023 Aug 1;41(22):3875. doi: 10.1200/JCO.23.00664. Epub 2023 Jun 2. J Clin Oncol. 2023. PMID: 37267582 No abstract available.
References
-
- Zarkhin F: OHSU to pay $1 million, promises change to settle lawsuit from widow of cancer patient, The Oregonian, 2022
-
- FDA : Capecitabine Package Insert. US Food and Drug Administration, Silver Spring, MD, 2021
-
- FDA : Fluorouracil Package Insert. US Food and Drug Administration, Silver Spring, MD, 2016
-
- Ciccolini J, Milano G, Guchelaar HJ: Detecting DPD deficiency: When perfect is the enemy of good. Cancer Chemother Pharmacol 87:717-719, 2021 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
